When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine

CNS Drugs

Volumn 21, Issue 4, 2007, Pages 267-278

  Kerwin, Robert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMATOLOGIC DISEASE; HUMAN; HYPERTRIGLYCERIDEMIA; META ANALYSIS; MORTALITY; MYOCARDITIS; NEUTROPENIA; OBESITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; SCHIZOPHRENIA;

EID: 34247153386     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721040-00002     Document Type: Review

References (61)

1. Baldessarini RJ, Frankenburg FR. Clozapine: a novel agent. N Engl J Med 1991; 324 (11): 745-54
2. Hippius H. The history of clozapine. Psychopharmacology 1989; 99: S3-5
3. Idanpaan HJ, Alhave E, Olkinnonora M, et al. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 94-8
4. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990; 40: 722-47
5. Claghorn J, Honigfield G, Abuzzahab FS. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377-84
6. Newcomer HJ, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychol 2006; 51: 480-91
7. Anderman B, Griffith RW. Clozapine induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 1977; 11: 199-201
8. Altamura AC, Bassetti R, Cattaneo E, et al. Some biological correlates of drug resistance in schizophrenia: a multidimensional approach. World J Biol Psychiatry 2005; 6 Suppl. 2: 23-30
9. Cole JD, Goldberg SC, Davis JM. Drugs in the treatment of psychosis: controlled studies. In: Solomon P, editor. Psychiatric drugs. New York: Groller and Stratton, 1966: 153-60
10. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29: 309-14
11. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
12. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812
13. Meltzer HY, Bastani B, Young-Kwon H, et al. A prospective study of clozapine in treatment resistant patients: a preliminary report. Psychopharmacology (Berl) 1989; 99 Suppl. 68: S68-72
14. Brier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151 (1): 20-6
15. Kane J, Marder SR, Schooler NR, et al. Efficacy of clozapine versus haloperidol in a long term clinical trial [abstract]. American Psychiatric Association Annual Meeting; 1995 May 20-25; Miami (FL)
16. Lieberman JA, Stroup T, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23
17. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611-22
18. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 606-10
19. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second versus first generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study (CUtLASS). Arch Gen Psychiatry 2006; 63: 1079-87
20. Lewis SW, Barnes TW, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bull 2006; 32: 715-36
21. Munro J, O'Sullivan D, Arana A, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576-80
22. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1998; 8: 671-7
23. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483-8
24. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59 Suppl. 3: 3-7
25. Bastani B, Alphs LD, Meltzer HG. Development of the Clozaril patient management system. Psychopharmacology (Berl) 1989; 99 Suppl.: S122-5
26. Johnstone EC, Crow TJ, Johnson AL, et al. The Northwick Park study of first episodes of schizophrenia: I. Presentation of the illness and problems relating to admission. Br J Psychiatry 1986; 148: 115-20
27. Crow TJ, MacMillan JF, Johnson AL, et al. Northwick Park study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-7
28. Lieberman JA, Jody D, Geisler SH, et al. Time course and biological correlates of treatment response to first episode schizophrenia. Arch Gen Psychiatry 1993; 50: 369-76
29. Larsen TK, Johannessen JO, Opjordsmoen S. First episode schizophrenia with long duration of psychosis: pathways to care. Brit Journal Psychiatry 1998; 172 Suppl. 33: 45-52
30. Barnes TRE, Hutton SB, Chapman MJ, et al. West London first episode study of schizophrenia: clinical correlates of duration of untreated psychosis. Br J Psychiatry 2000; 177: 207-11
31. Loebel AD, Lieberman JA, Alum JM, et al. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry 1992; 149: 1183-8
32. Perkins DO, Gu K, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in first episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-804
33. Norman RMG, Lewis SW, Marshall M. Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry 2005; 187: S19-23
34. Lieberman JA, Tollefson GD, Zipursky CC, et al. Antipsychotic drug effects on brain morphology in first episode psychosis. Arch Gen Psychiatry 2005; 62: 361-76
35. Verdoux H, Bergey C, Assens F, et al. Prediction of duration of psychosis before first admission. Eur Psychiatry 1998; 13: 346-52
36. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment naïve first episode schizophrenia: a 52 week randomised trial of clozapine versus chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003
37. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30-4
38. Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 1990; 147: 602-7
39. Nyman A, Jonsson H. Patterns of self destructive behaviour in schizophrenia. Acta Psychiatrica Scandinavica 1986; 73: 252-62
40. Arelsson R, Lagerkuist-Briggs M. Factors predicting suicide in psychotic patients. Eur Arch Psychiatry Clin Neurosci 1992; 241: 259-66
41. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk benefit assessment. Am J Psychiatry 1995; 152: 183-90
42. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). N Engl J Med 2003; 60: 82-91
43. Alphs L, Anand R, Islam MZ, et al. The International Suicide Prevention Trial (InterSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behaviour in schizophrenia and schizophrenic patients. Schizophrenia Bull 2004; 30: 577-86
44. Duggan A, Warner J, Knapp M, et al. Modelling the impact of clozapine on suicide in patients with treatment resistant schizophrenia in the UK. Br J Psychiatry 2003; 182: 505-8
45. Modestin J, Dal Pian D, Argawalla P. Clozapine diminishes suicidal behaviour: a retrospective evaluation of clinical records. J Clin Psychiatry 2005; 66: 534-8
46. Sernyak MJ, Hoff R, Rosenheck MD. Clozapine and suicide [letter]. Psychiatric Serv 1999; 50: 116
47. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta analysis. Schizophr Res 2005; 73: 139-45
48. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001; 158: 1449-54
49. Davis JM, Chen N, Glick ID. A meta analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64
50. Tiihonan J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333 (7561): 224. Epub 2006 Jul 6
51. Angst J, Bente D, Berner P. Das klinische wilkungbild von clozapine. Pharmako-Psychiatrie 1971; 4: 200-11
52. Green AI, Schildkraut JJ. Should clozapine be a first line treatment for schizophrenia? The rationale for a double blind clinical trial in first episode patients. Harv Rev Psychiatry 1995; 3: 1-9
53. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-51
54. Woerner G, Robertson DG, Alvil MA, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003; 160: 1514-6
55. Lieberman JA, Alvil JM, Woerner G, et al. Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital. Schizophr Bull 1992; 18: 351-71
56. Kelly DL, Conley RR, Carpenter WT. First episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005; 65: 1113-38
57. Hofer A, Hummer M, Kemmier G, et al. The safety of clozapine in the treatment of first and multiple episode patients with treatment resistant schizophrenia. Int J Neuropsychopharmacology 2003; 6: 201-6
58. Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third line status for schizophrenia: a decision analytic model. J Ment Health Policy Econ 2004; 7: 77-85
59. National Institute for Healthcare and Clinical Excellence (NICE): Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal no. 43, 2002 [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Dec 18]
60. Royal Australian and New Zealand College of Psychiatrists. Clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39: 1-30
61. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd draft. Washington, DC: American Psychiatric Association, 2003